Precigen (PGEN) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precigen (PGEN) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 8.5% versus a loss of 24.6%. Over five years, PGEN leads with a +9.1% price change compared with -83.3% for SRPT. Precigen is the larger company by market cap ($1.51 billion vs $1.43 billion), about 1.1 times the size.
On valuation, Precigen trades at a lower trailing P/E (38.3x vs 666.5x for Sarepta Therapeutics). Sarepta Therapeutics converts more of its revenue into profit, with a net margin of -32.5% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PGEN | SRPT |
|---|---|---|
| Share price | $4.21 | $13.33 |
| Market cap | $1.51B | $1.43B |
| 1-day change | +1.20% | -5.93% |
| YTD return | +0.72% | -38.06% |
| 1-year return | +8.51% | -24.65% |
| 5-year return | +9.07% | -83.26% |
| P/E ratio (TTM) | 38.27 | 666.50 |
| Forward P/E | — | 8.87 |
| EPS (TTM) | $0.11 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.68M | $2.20B |
| Revenue growth (YoY) | +146.73% | +15.58% |
| Net income (latest FY) | $-250.64M | $-713.41M |
| Gross margin | — | 98.84% |
| Operating margin | -1141.13% | -31.83% |
| Net margin | -2588.21% | -32.45% |
| 52-week high | $8.98 | $24.68 |
| 52-week low | $3.04 | $13.25 |
| Distance from 52-week high | -53.12% | -45.99% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +224.70% | +63.32% |
| Average volume | 5.68M | 2.70M |
| Shares outstanding | 358.55M | 107.24M |
| Employees | 160 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed SRPT by 33.2 percentage points over the past year.
- Sarepta Therapeutics trades at a higher earnings multiple (666.5x vs 38.3x trailing P/E).
- Sarepta Therapeutics is more profitable, keeping -32.5 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs +15.58%).
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
PGEN vs SRPT FAQ
Which is bigger, Precigen or Sarepta Therapeutics?
Precigen (PGEN) is larger, with a market capitalization of $1.51B compared with $1.43B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, PGEN or SRPT?
PGEN returned +8.51% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PGEN or SRPT?
PGEN has the lower trailing P/E at 38.3, versus 666.5 for SRPT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Precigen and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.